PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation
Abstract Patients with secondary acute myeloid leukemia (sAML) arising from myelodysplastic syndromes have a poor prognosis marked by an increased resistance to chemotherapy. An urgent need exists for adjuvant treatments that can enhance or replace current therapeutic options. Here we show the poten...
Saved in:
Main Authors: | Chao Hu, Mengxia Yu, Yanling Ren, Kongfei Li, Dominic M. Maggio, Chen Mei, Li Ye, Juying Wei, Jie Jin, Zhengping Zhuang, Hongyan Tong |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2017
|
Subjects: | |
Online Access: | https://doaj.org/article/989b895b4d6c446dbb40e8e4801513f0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TIFAB accelerates MLL-AF9−Induced acute myeloid leukemia through upregulation of HOXA9
by: Jinming Zhao, et al.
Published: (2021) -
INVESTIGATION ON LAMINATED WOOD (LB, LVL) MANUFACTURING
by: Ahmad Jahan latibari, et al.
Published: (2001) -
Differentiation therapy for myeloid malignancies: beyond cytotoxicity
by: Ryan J. Stubbins, et al.
Published: (2021) -
Synthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticles
by: Jun Wang, et al.
Published: (2011) -
Acta Nº181
by: Banco Central de Chile
Published: (2019)